Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cargene Biopharma

Request full access

Oligonucleotide therapeutics for cardiovascular, fibrotic, and pulmonary diseases

SingaporeFounded 2020Biotech & Life Sciences

About Cargene Biopharma

Cargene Biopharma is a preclinical-stage biopharmaceutical company founded in 2020, with operations in Singapore, the USA, and China. The company develops oligonucleotide therapeutics to treat a range of conditions, primarily focusing on cardiovascular, fibrotic, and pulmonary diseases, as well as ophthalmic disorders.

The company was co-founded by XQ Lin, the founder and Chairman of EVX Ventures; Dr. Yann Chong Tan, a serial biotech entrepreneur; and Dr. Torsten Wuestefeld, a principal investigator at A*STAR’s Genome Institute of Singapore. In June 2022, Kathy He, a veteran biopharmaceutical executive with over 20 years of experience, was appointed as CEO. Cargene's scientific advisory board includes world-class scientists such as Professors Harvey Lodish, Roger Foo, and Kausik Ray.

Cargene utilizes proprietary technology platforms, including the OSCAR™ algorithm and SMoP™ pharmacophore design, to create highly potent, specific, and stable small interfering RNAs (siRNAs). These platforms are aimed at addressing previously undruggable targets. One of its initial programs focuses on non-alcoholic steatohepatitis (NASH), using in-licensed technology from Singapore's Agency for Science, Technology and Research (A*STAR) to reduce liver fibrosis and enhance liver regeneration. The company is also developing technologies for targeted delivery of oligonucleotides to various tissues.

In December 2021, Cargene closed an oversubscribed pre-Series A funding round of $19.2 million. The financing was led by BioTrack Capital and included participation from Hyfinity Investments and Legendstar Capital. These funds are intended to advance the company's lead asset to an Investigational New Drug (IND) application and to further develop its technology platforms.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Singapore
Employees
3
Open positions
None listed
Dealroom signal
60.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Techbio, DT and LS, science-based

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Dec 2021 $19M $77M Hyfinity Investments · BioTrack Capital ↗
SPINOUT✓Other financing Jan 2020 $0 — A-STAR —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Cargene Biopharma website traffic

Latest recorded traffic for Cargene Biopharma is 590 monthly website visits, down 35.2% over the last three months. Cargene Biopharma's team declined 25% over the past year.

Latest monthly visits590 3-month web change-35.2% 1-year team growth-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cargene Biopharma in its local ecosystem

Live from Dealroom

The Cargene Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • BioTrack Capital
  • Hyfinity Investments

Other known investors2 additional known investors

  • A-STAR
  • EVX Ventures
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇸🇬 Singapore75%
🇺🇸 United States25%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cargene Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cargene Biopharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.